Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy

The cure rate for pediatric patients with B precursor acute lymphoblastic leukemia (pre-B ALL) is steadily improving, however relapses do occur despite...

News & Events

Rapid diagnosis for childhood brain cancer in WA

The Kids Research Institute Australia's Brain Tumour Research team will develop and implement cutting-edge technologies to revolutionise the speed of brain cancer diagnosis for WA children, thanks to more than $200,000 from Telethon.

Research

Successful treatment of a child with acute monoblastic leukaemia who relapsed with T-cell acute lymphoblastic leukaemia: A rare lineage switch

Rishi S. Kotecha MB ChB (Hons) MRCPCH FRACP PhD Co-Head, Leukaemia Translational Research rishi.kotecha@health.wa.gov.au Co-Head, Leukaemia

Research

Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia

Children with Down syndrome (constitutive trisomy 21) that develop acute lymphoblastic leukemia (DS-ALL) have a 3-fold increased likelihood of treatment-related mortality coupled with a higher cumulative incidence of relapse, compared with other children with B-cell acute lymphoblastic leukemia (B-ALL).

Research

Accumulation of CD103+ CD8+ T cells in a cutaneous melanoma micrometastasis

Results support the emerging concept that CD103+ CD8+ tissue‐resident memory T cells are key mediators of cancer surveillance

Research

The dystroglycan receptor maintains glioma stem cells in the vascular niche

These findings reveal a central role of the DG receptor, not only as a structural element, but also as a critical factor promoting mesenchymal-like GBM

Research

PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein

Our findings present a novel mouse model for glioma demonstrating that the PI3K pathway is important for initiation of tumorigenesis

Research

Boosting the influenza vaccine schedule in children with cancer: a prospective open-label study

Current immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children's Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule.